Novakand Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Other Revenue	0.01	-	-	-	-
Revenue	0.01	-	-	-	-
Gross Profit	0.01	-	-	-	-
Selling, General & Admin	6.05	6.22	8.09	7.08	4.33
Research & Development	23.56	39.95	57.99	45.61	42.63
Other Operating Expenses	-	-0.01	-	-	-0
Operating Expenses	29.61	46.16	66.08	52.69	46.96
Operating Income	-29.59	-46.16	-66.08	-52.69	-46.96
Interest Expense	-	-	-	-0.12	-0.02
Interest & Investment Income	-	1.6	0.28	0.07	-
Currency Exchange Gain (Loss)	-	-	0.45	-0.09	-0.25
Other Non Operating Income (Expenses)	0.37	-	0.46	0.34	1.54
EBT Excluding Unusual Items	-29.23	-44.57	-64.89	-52.48	-45.69
Asset Writedown	-18	-	-	-	-
Pretax Income	-47.23	-44.57	-64.89	-52.48	-45.69
Net Income	-47.23	-44.57	-64.89	-52.48	-45.69
Net Income to Common	-47.23	-44.57	-64.89	-52.48	-45.69
Shares Outstanding (Basic)	121	115	80	58	56
Shares Outstanding (Diluted)	121	115	80	58	56
Shares Change (YoY)	5.08%	44.85%	36.90%	3.91%	54.18%
EPS (Basic)	-0.39	-0.39	-0.81	-0.90	-0.82
EPS (Diluted)	-39.00	-0.39	-0.81	-0.90	-0.82
Free Cash Flow	-30.29	-58.53	-55.67	-47.56	-44.13
Free Cash Flow Per Share	-0.25	-0.51	-0.70	-0.82	-0.79
Gross Margin	100.00%	-	-	-	-
Operating Margin	-211385.71%	-	-	-	-
Profit Margin	-337350.00%	-	-	-	-
Free Cash Flow Margin	-216350.00%	-	-	-	-
EBITDA	-	-43.16	-63.08	-52.33	-46.64
D&A For EBITDA	-	3	3	0.36	0.32
EBIT	-29.59	-46.16	-66.08	-52.69	-46.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.